2024-516852-17-00招募中2 期
Clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia with open-label Part I and randomized, double-blind, placebo-controlled Part II.
Adeptio Pharmaceuticals Limited8 个研究点 分布在 4 个国家目标入组 102 人开始时间: 2024年9月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 102
- 试验地点
- 8
- 主要终点
- Change in AIMS score (items 1 through 7) from Baseline (Day 0) to Week 12, as assessed by central rating.
研究概览
简要总结
To evaluate efficacy of ADE513 in reducing abnormal involuntary movements of tardive dyskinesia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Part II
- 盲法
- Double (Analyst, Monitor, Carer, Investigator, Subject)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Subject aged between 18 and 75 years, inclusive.
- •Subject in good general health with expectation to attend all study visits and complete all study assessments as judged by the Investigator.
- •Subject able to read, comprehend and provide the written informed consent.
- •Subject able to complete subject-facing rating scales.
- •Female subject of childbearing potential who agrees to use a highly effective form of contraception (as defined by the Protocol) throughout the Study.
- •Subject with a clinical diagnosis of tardive dyskinesia.
- •Subject with symptoms of TD which are bothersome and/or cause functional impairment.
- •Subject with total motor AIMS score of ≥6, and with abnormal movements judged as moderate or severe by the Investigator (based on Item 8 of the AIMS).
- •Subject with body weight of not less than 45kg for females and 55kg for males.
- •Subject in a psychiatrically stable condition with no change in psychoactive medications (eg. Neuroleptics, benzodiazepines, anticonvulsants, mood stabilizers etc.) within the last 30 days before Screening, and with no anticipated changes to the subject’s treatment regimen in the next 3 months.
- •Subject living in a stable environment as judged by the Investigator, with adequate supervision when necessary.
- •Subject having a caregiver who is in regular personal contact with the subject (no less than 5 days a week); if locally required.
- •Subject compliant with prescribed treatment regimen as judged by the Investigator.
排除标准
- •Subject who received any of the following medications within 30 days of Screening or Baseline: o Tetrabenazine, deutetrabenazine, valbenazine, reserpine, α-methyl-p-tyrosine (AMPT), o Trihexyphenidyl, orphenadrine, procyclidine, biperiden or other strong anticholinergics o Metoclopramide, promethazine, and prochlorperazine o Methylphenidate, amphetamine/dextroamphetamine, or other stimulants, o Monoamine oxidase inhibitors (MAOIs) o Levodopa or dopamine agonists o Botulinum toxin (within 3 months of Screening) Note: Existing medication for the subject’s TD symptoms must not be discontinued solely for the purpose of inclusion in this clinical trial.
- •Subject with clinically significant cardiac abnormality or QTcF >450 ms (males) or >470 ms (females) on 12-lead ECG at Screening.
- •Subject with any of the following abnormal values in laboratory test results at Screening: o aspartate transaminase (AST) or alanine aminotransferase (ALT) >2.5 times the upper limit of normal (ULN) o alkaline phosphatase (ALP) or total bilirubin >2 times the ULN, o serum creatinine >1.5 times the ULN o any other results outside of laboratory reference ranges judged as clinically significant by the Investigator o positive hepatitis B surface antigen (HbSAg, indicating ongoing hepatitis B infection), or positive human immunodeficiency virus antibody (HIV-Ab) or positive hepatitis C antibodies (HCV) test result.
- •Subject with a known allergy or hypersensitivity to any component of ADE513, or to a VMAT2 inhibitor e.g. tetrabenazine, deutetrabenazine, valbenazine.
- •Subject who has received any investigational drug product within 30 days (or 5 drug half-lives, if longer than 30 days) of Screening.
- •Subject acknowledging present alcohol or substance abuse at Screening, or subject with a history thereof within 12 months of Screening, or subject expected to be unable to refrain from substance abuse during the study.
- •Subject with a positive urine drug screen at Screening.
- •Pregnant or breastfeeding subject.
- •Applicable only to investigator sites in Slovakia: Subject with presence of parkinsonism, pheochromocytoma and prolactin dependent tumours, e.g. pituitary or breast cancer.
- •Subject with a neurological condition that may interfere with the assessment of dyskinesia severity.
- •Subject with a serious psychiatric condition that is untreated or undertreated at Screening and/or Baseline.
- •Subject with active suicidal ideation at Screening or Baseline.
- •Subject with history of either previous intent to act on a suicidal ideation with a specific plan, or previous preparatory acts to commit suicide or suicidal behaviour, or a previous actual, interrupted or aborted suicide attempt.
- •Subject with an abnormal score on the depression subscale of the Hospital Anxiety and Depression Scale (HADS) at Screening or Baseline. Abnormal score is defined as score ≥
- •Subject with an unstable or serious medical condition at Screening or Baseline.
- •Subject with developmental disability or evidence of dementia confirmed by Mini-Mental State Exam (MMSE score ≤24).
- •Subject showing violent behaviour, or subject with a history thereof within 3 months of start of study participation.
结局指标
主要结局
Change in AIMS score (items 1 through 7) from Baseline (Day 0) to Week 12, as assessed by central rating.
Change in AIMS score (items 1 through 7) from Baseline (Day 0) to Week 12, as assessed by central rating.
次要结局
- Part I Secondary Endpoints: - Change in AIMS score (items 1 through 7) from Baseline (Day 0) to Week 12) in Part I, as assessed by the on-site Investigator. - Change in AIMS score (items 1 through 7 from Baseline (Day 0) to Week 9 in Part I, as assessed by the on-site Investigator. - Change in AIMS score (items 1 through 7) from Week 6 to Week 12 in Part I, as assessed by the on-site Investigator.
- Part II Secondary Endpoints: - Dose level associated with adequate control of dyskinesia (defined as dose level used in Maintenance period) in Part II. - Proportion of subjects with the value of Much or Very Much Improved on the Clinical Global Impression of Change (CGIC) at Week 12 in Part II. - Proportion of subjects with the value of Much or Very Much Improved on the Patient Global Impression of Change (PGIC) at Week 12 in Part II.
研究者
Andrew Duffield
Scientific
Adeptio Pharmaceuticals Limited
研究点 (8)
Loading locations...
相似试验
进行中（未招募）
不适用
Clinical trial to assess diaphragm´s function after local anaesthetic infiltration compared to placebo in order to avoid post-surgery pain in patients undergoing thoracic surgery.EUCTR2014-005062-30-ESniversity Hospital Germans Trias i Pujol
已完成
2 期
Randomized, double-blind, placebo-controlled clinical trial of sublingual immunotherapy in natural rubber latex allergic patientsatex allergyInflammatory and Immune System - AllergiesLatex allergyACTRN12611000543987Allergy Service. Hospital Santiago Apostol28
进行中（未招募）
1 期
The aim of the study is to analyze whether the administration of a vaccine against COVID19 infection can reduce the symptoms of long COVID.nlike what happens with other respiratory viruses, in a significant proportion of patients who have suffered from the disease, general and multi-organ symptoms may persist for months, which has been called long COVIDEUCTR2021-003331-28-ESFelix Gutierrez Rodero776
进行中（未招募）
1 期
Evaluation of the Immodin effectiveness on the immune system of healthy volunteersEUCTR2012-001709-26-CZSevapharma,a.s.
进行中（未招募）
3 期
Placebo-controlled clinical trial to evaluate the efficacy and safety of hydroxychloroquine and azithromycin in relation to placebo in the negative viral load of participants with SARS-CoV2 flu syndrome and who do not have an indication for hospitalizatioRBR-95yjmqHospital Santa Paula